{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:44:17Z","timestamp":1764171857626,"version":"3.46.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Key Clinical Specialty Construction Project","award":["U114000","U114000","U114000","U114000","U114000","U114000"],"award-info":[{"award-number":["U114000","U114000","U114000","U114000","U114000","U114000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01865-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:36:49Z","timestamp":1764171409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura"],"prefix":"10.1186","volume":"18","author":[{"given":"Peiyao","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmiao","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tienan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xirun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"6","key":"1865_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1865_CR2","first-page":"284","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"1865_CR3","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194\u2013200.","journal-title":"J Clin Oncol"},{"issue":"7035","key":"1865_CR4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"12","key":"1865_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1865_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN guidelines\u00ae insights: ovarian cancer\/Fallopian tube cancer\/primary peritoneal cancer, version 3.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2024;22(8):512\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/ejh.14351","volume":"114","author":"SR Chowdhury","year":"2025","unstructured":"Chowdhury SR, Sirotich E, Guyatt G, Gill D, Modi D, Venier LM, et al. Treatment of critical bleeds in patients with immune thrombocytopenia: a systematic review. Eur J Haematol. 2025;114(3):458\u201368.","journal-title":"Eur J Haematol"},{"key":"1865_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.","journal-title":"BMJ"},{"key":"1865_CR9","doi-asserted-by":"publisher","first-page":"S779","DOI":"10.1016\/j.annonc.2022.07.645","volume":"33","author":"P DiSilvestro","year":"2022","unstructured":"DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. 517O overall survival (OS) at 7-year (y) follow-up (f\/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance Olaparib in the SOLO1\/GOG-3004 trial. Ann Oncol. 2022;33:S779.","journal-title":"Ann Oncol"},{"issue":"1","key":"1865_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.critrevonc.2011.02.004","volume":"81","author":"MT Krauth","year":"2012","unstructured":"Krauth MT, Puthenparambil J, Lechner K. Paraneoplastic autoimmune thrombocytopenia in solid tumors. Crit Rev Oncol Hematol. 2012;81(1):75\u201381.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1865_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1111\/jog.12731","volume":"41","author":"T Shimada","year":"2015","unstructured":"Shimada T, Saito T, Choi I, Yamaguchi S, Shimamoto K, Ariyoshi K, et al. Immune thrombocytopenia associated with solid cancer. J Obstet Gynaecol Res. 2015;41(9):1495\u20138.","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"1865_CR12","first-page":"539","volume":"24","author":"A Chehal","year":"2003","unstructured":"Chehal A, Taher A, Seoud M, Shamseddine A. Idiopathic thrombocytopenic purpura and ovarian cancer. Eur J Gynaecol Oncol. 2003;24(6):539\u201340.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"4","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10147-010-0149-3","volume":"16","author":"K Wakana","year":"2011","unstructured":"Wakana K, Yasugi T, Nako Y, Nei T, Ozaki Y, Mizutani K. Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura. Int J Clin Oncol. 2011;16(4):447\u20139.","journal-title":"Int J Clin Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01865-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:36:50Z","timestamp":1764171410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01865-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01865-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"286"}}